The Biotech Trek: A Short History from 1993 to 2021
June 29, 2021
The Nasdaq Biotechnology Index (NBI) launched in 1993, when the industry was still in the midst of the original “biotech revolution.” Since then, its constituent basket has swelled from roughly 100 components to 274, reflecting the tremendous growth in the small cap space – the overwhelming majority of which has stemmed from IPOs on the Nasdaq Stock Exchange.
As the biotech industry enters a new phase of growth, it’s more important than ever for investors to consider their allocations toward the space.
In the upcoming webcast,
The Biotech Trek: A Short History from 1993 to 2021, Rene Reyna, Head of Thematic and Specialty Product Strategy ETFs and Indexed Strategies, Invesco; and Mark Marex, Research & Development Specialist, Nasdaq Global Indexes, will discuss the regulatory, scientific, and demographic factors driving today’s growth in biotech and why the Nasdaq Biotechnology Index’s methodology leads to the best representation of the sector.